Production (Stage)
Tenax Therapeutics, Inc.
TENX
$6.07
$0.020.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 109.36% | 79.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 55.43% | 57.93% | |||
| Operating Income | -55.43% | -57.93% | |||
| Income Before Tax | -66.08% | -58.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -66.08% | -58.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -66.08% | -58.24% | |||
| EBIT | -55.43% | -57.93% | |||
| EBITDA | -- | -57.96% | |||
| EPS Basic | -60.19% | 5.13% | |||
| Normalized Basic EPS | -60.18% | 5.13% | |||
| EPS Diluted | -60.19% | 5.13% | |||
| Normalized Diluted EPS | -60.18% | 5.13% | |||
| Average Basic Shares Outstanding | 3.66% | 66.79% | |||
| Average Diluted Shares Outstanding | 3.66% | 66.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||